Background: Iliac vein stenting technology is rapidly emerging as a minimally invasive alternative to traditional open venovenous bypass procedures for iliac vein stenoses and chronic total occlusions. Methods: Peer-reviewed publications meeting eligibility criteria were retrieved and reviewed from public domain databases. Results: Reviewed reports encompass w1500 patients. Evidence quality was judged moderate, with a grade 1B recommendation (benefits outweigh risks) for patients with disabling symptoms in whom conservative therapy had failed. A grade 2B recommendation was assigned for patients with less severe symptoms. Iliac vein stenting is safe, with negligible morbidity (<1%). Patency was 90% to 100% for nonthrombotic disease and 74% to 89% for post-thrombotic disease at 3 to 5 years. Clinical relief of pain was 86% to 94%, and relief from swelling was 66% to 89%. From 58% to 89% of venous ulcers healed. Procedural success in recanalization of chronic total occlusions was 83% to 95%. Hybrid techniques for complex cases are in evolution. Conclusions: Iliac vein stenting is emerging as a safe and effective alternative to traditional open surgery to correct iliac vein obstruction. (J Vasc Surg 2013;57:1163-9.) 
Venous stent technology has rapidly evolved as the initial procedure of choice in the treatment of iliofemoral stenosis and chronic total occlusions (CTO). Open surgery, the prior standard, is now reserved only for stent failures. Concurrently, the use of intravascular ultrasound (IVUS) imaging, essential for proper stent placement, has broadened the scope of stent treatment to include primary nonthrombotic iliac vein lesions (NIVL). Previously, obstruction in this genre was thought to be relatively rare, largely due to the poor diagnostic sensitivity of venography.
The pivotal role of iliac vein stenoses as a cause of recurrent thrombosis and in the development of post-thrombotic syndrome (PTS) is now well recognized. Clinical relief, including ulcer healing, occurs with iliac vein stenting even in the presence of significant reflux, an intriguing finding with fundamental pathophysiologic implications.
Iliac vein stenting appears to be safe and effective, as reviewed below; the technique is easier to learn and use than open surgery, potentially benefitting a larger proportion of patients. Because open surgery is not precluded afterwards, iliac vein stenting is in a different class from traditional venous bypass techniques, and strict efficacy comparisons are moot in a disease that seldom poses a threat to limb or life. Accordingly, this evidence review focuses on the iliac vein stent literature, and some key references to open procedures are included to provide context.
METHODS
Peer reviewed articles in English were retrieved from public domain databases with the following search terms: "common iliac vein; iliac vein; iliofemoral vein; stenosis; venous occlusion; postthrombotic syndrome; MayThurner syndrome; Cockett syndrome; iliac vaso compression syndrome," and "venous stent." All were listed in Medline. The voluminous literature dealing with acute occlusions was excluded because disease progression is likely different. For outcome analysis, a selection threshold of at least 25 limbs treated for chronic occlusions with a minimum follow-up of 3 years was applied. None that met the threshold were excluded; some below the threshold and ancillary references have been selectively included to highlight special features of interest.
RESULTS
All studies reviewed are single-arm retrospective case series. The quality of evidence 1 for stent treatment was graded as moderate. The consistency of the evidence and the magnitude of effects, such as ulcer healing, for example, suggest a grade 1B recommendation (strong recommendation, benefits outweigh risks) for patients with disabling symptoms in whom conservative therapy has failed. Complex surgical procedures, such as venovenous bypass or deep valve reconstruction, were the only available options for such patients before. A grade 2B recommendation was assigned for patients with less severe symptoms.
Clinical features and pathophysiology
Symptomatic iliac-caval obstruction of NIVL or PTS etiology can present with a wide range of clinical features, including all clinical CEAP classes. Specific correction is seldom warranted unless advanced symptoms (CEAP clinical class $3 or significant pain). Orthostatic limb pain is a pervasive feature but may be absent in w20% to 30% of patients; it may be the only clinical manifestation sans other clinical features in 10% to 15% of patients (CEAP #2). Excellent pain relief may be obtained by stent treatment. 2 Recurrent cellulitis, especially the spontaneous variety, may be indicative of an underlying iliac obstructive lesion amenable to correction and relief. 3 Iliac vein thrombosis secondary to an obstructive lesion is well known, with a voluminous literature that is not reviewed here.
A confusing feature is the presence of iliac caval pathology in a wide swath of the general population in silent form. This has been a source of controversy in attributing pathologic significance to a ubiquitous lesion. A possible explanation to connect progression of a silent lesion into a symptomatic one is the concept that the lesion functions in a permissive fashion. 4 Regardless, there is little doubt that correction of iliac stenosis remits symptoms if they occur.
Diagnosis
Diagnosis of iliac-caval obstruction remains hobbled by the relative insensitivity of contrast venography (Table I) . This is because many iliac vein lesions are visible only in one plane and membranous lesions may not be visible at all. Perivenous and wall fibrosis are impervious to venography; diffuse long stenoses common in post-thrombotic disease are easily missed. Computed tomography or magnetic resonance imaging techniques may have similar sensitivity issues, 12 but comparative studies to assess diagnostic accuracy are as yet unavailable.
Intravascular ultrasound (IVUS) imaging has emerged as a promising new diagnostic tool with apparently higher sensitivity and greater diagnostic yield (Table I) . Previously, symptomatic NIVL incidence was thought to be relatively rare, with w3% of the population with chronic venous disease involving predominantly the left lower limb of young women. Use of IVUS imaging has shown that iliac-caval obstructions occur as commonly in nonthrombotic cases as in post-thrombotic limbs, affecting both sexes, all age groups, and both sides. This lesion, first described by McMurrich in 1908, was more clearly defined by several authors, notably by May and Thurner (1957) and later Cockett (1965 . Earlier autopsy studies 14 and current IVUS findings clearly indicate that NIVL are complex lesions involving not only external compression but also wall fibrosis, intraluminal webs, and membranes. The term "iliac compression syndrome" is, therefore, a misnomer.
The lesion is clearly nonthrombotic because it lacks the pathognomic vascular invasion. A traumatic etiology from pulsations of the intimately related artery is probably the major cause, although an ontogenic origin is likely in some, because the lesions, particularly membranous ones, occur at embryologic fusion planes. 14, 15 The lesion has been occasionally discovered in young children. 14, 16 Intraperitoneal fibrosis, tumor, and other extrinsic causes of iliac vein obstruction are relatively rare, accounting for w5% of cases.
Treatment options
A variety of open, closed, and hybrid techniques are now available for treating iliac vein obstructions (Table II) .
Evidence summary
Technical outcome of iliac vein stenting. Stent treatment appears to be a safe procedure. Among the w1500 patients in the series reviewed, no deaths or pulmonary embolus were reported. Access site complications occurred in <1% and significant bleeding requiring transfusions in <0.03%. The incidence of postoperative and interval long-term deep venous thrombosis appears to be no different from the incidence of native disease. Stent-related complications, such as stent fracture, erosions, late embolization, and infections, are extremely rare. It is not clear if this is related to the specific type of stent used. All of the reviewed series, except one (information missing), reported using self-expanding large-caliber Wallstents (Boston Scientific, Natick, Mass) in most of the patients. Other complications, such as back pain, occur early after the procedure and are generally minor and self-limited.
Stent patency (Table III) has been surprisingly good, considering the propensity for thrombosis in the venous system with low velocity flow. Stent thrombosis is an extreme rarity in NIVL disease as reported, an astonishing statistic considering arterial stent experience. Approximately 25% of stents occlude in thrombotic cases during a 3-to 5-year period. Secondary patency has ranged from 90% to 100% in NIVL limbs and from 74% to 89% in post-thrombotic limbs during 4 to 7 years. Patency is somewhat lower, at 66% to 89% at 4 to 7 years, and stent occlusions higher in the group among CTO recanalizations. Factors associated with stent occlusion include prior thrombosis, male sex, recent trauma, and age <40 years, with a combination of factors exponentially decreasing long-term patency. 31 Thrombophilia did not affect stent outcome in several series. Technical success of CTO recanalizations has ranged from 83% to 95%.
Mild in-stent restenosis (ISR) is common, but significant lesions ($50%) occur in w10% of post-thrombotic cases; it is extremely rare in the NIVL subset (1%). ISR incidence is related to thrombophilia, prior thrombosis, and use of a long stent. 21 Limited experience indicates that pregnancy can be tolerated after placement of selfexpanding stents. 35 Use of anticoagulation during and after stent placement has varied. Although some authors have used postoperative warfarin anticoagulation for several months after the procedure, it does not seem to be necessary in NIVL. 2, 30, 31 Patency rates appear not to be affected with use of only aspirin after stent placement in this subset.
Clinical outcome. Clinical relief has been good to excellent, as reported, and the results appear to be durable (Table IV) . Relief of pain is excellent, ranging from 86% to 94%, with total relief in most. Swelling relief is good, ranging from 66% to 89%. Interestingly, ulcer healing occurs in 58% to 89% of patients after stent placement, even without correction of associated reflux. 36, 37 Two of the larger series reported improvement in quality of life parameters.
Iliac vein stents have been placed in stenosed or occluded iliac veins to maintain dialysis access and in pediatric patients with congenital heart defects to gain access for catheterization. 38 Iliac vein occlusion may lead to neurogenic claudication due to collateral congestion in the spinal canal affecting the cord or cauda equina; diagnosis is made with magnetic resonance or computed tomography imaging. Relief with iliac vein stenting has been reported. 39 One reviewed series 30 reported relief of pelvic congestion in a large subset after iliac vein stent placement.
Areas needing further study. Many areas related to iliac vein stenting require further study and clarification, including the role of IVUS imaging (used in only two studies), the degree of correctible stenosis, the relationship between silent and symptomatic obstructions, interrelationship of obstruction and reflux, and finally, a hemodynamic metric for obstruction.
CONCLUSIONS
Stent placement to correct iliac-caval-femoral obstructions is emerging as a safe, effective, and minimally invasive alternative to traditional open surgery. 
